Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial.
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Lamivudine/zidovudine
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 01 Mar 2011 Effects on bone mineral density published in HIV Medicine.
- 01 Mar 2011 Status changed from active, no longer recruiting to completed.
- 24 Mar 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.